VIDEO: More data support first FDA-approved drug to treat Alzheimer’s-related agitation

PHILADELPHIA — In this Healio Video Perspective from the Alzheimer’s Association International Conference, Johan Luthman, PhD, discusses new data from post hoc analyses evaluating the efficacy of Rexulti for Alzheimer’s-related agitation.

“This is the first time ever a drug got approved for behavioral psychological symptoms in Alzheimer’s disease, which are very devastating symptoms,” said Luthman, executive vice president and head of research and development at Lundbeck.

Data from one study showed that Rexulti (brexpiprazole, Otsuka/Lundbeck) reduced the frequency of agitation symptoms, including “restlessness, night wandering and verbal agitation,” Luthman said.